Filters: Keyword is Buprenorphine [Clear All Filters]
"The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S178-83. Abstract
"HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S22-32. Abstract
"Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone." Journal of addiction medicine 6, no. 4 (2012): 274-9. Abstract
"Patient satisfaction with primary care office-based buprenorphine/naloxone treatment." Journal of general internal medicine 22, no. 2 (2007): 242-5. Abstract
"Integrating buprenorphine treatment into office-based practice: a qualitative study." Journal of general internal medicine 24, no. 2 (2009): 218-25. Abstract
"Models for integrating buprenorphine therapy into the primary HIV care setting." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 42, no. 5 (2006): 716-21. Abstract
"Provider satisfaction with office-based treatment of opioid dependence: a systematic review." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 26, no. 1 (2005): 15-22. Abstract
"A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice." Expert review of clinical pharmacology 6, no. 3 (2013): 249-69. Abstract
"Additional explanation for lack of pharmacodynamic interaction between atazanavir and buprenorphine reported by Vergara-Rodriquez et al." Journal of acquired immune deficiency syndromes (1999) 58, no. 4 (2011): e112; author reply e112-3.
"Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone." The American journal of drug and alcohol abuse 37, no. 4 (2011): 224-8. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone." Drug and alcohol dependence 105, no. 3 (2009): 234-9. Abstract
"Case series of buprenorphine injectors in Kuala Lumpur, Malaysia." The American journal of drug and alcohol abuse 34, no. 4 (2008): 511-7. Abstract
"Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases." The American journal of drug and alcohol abuse 33, no. 6 (2007): 869-74. Abstract
"Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir." Journal of acquired immune deficiency syndromes (1999) 54, no. 5 (2010): 511-4. Abstract
"Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice." Journal of acquired immune deficiency syndromes (1999) 41, no. 5 (2006): 563-72. Abstract
"Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market." The American journal of drug and alcohol abuse 35, no. 2 (2009): 68-72. Abstract
"HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications." The International journal on drug policy 18, no. 4 (2007): 326-8. Abstract
"Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir." AIDS (London, England) 20, no. 5 (2006): 783-4.
"Assessing social risks prior to commencement of a clinical trial: due diligence or ethical inflation?" The American journal of bioethics : AJOB 9, no. 11 (2009): 48-54. Abstract
"Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S14-21. Abstract
"Heroin dependence and HIV infection in Malaysia." Drug and alcohol dependence 82 Suppl 1 (2006): S39-42. Abstract
"Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence." Journal of substance abuse treatment 33, no. 4 (2007): 411-5. Abstract
"Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms." Journal of substance abuse treatment 29, no. 4 (2005): 307-12. Abstract
"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females." The pharmacogenomics journal 14, no. 3 (2014): 303-8. Abstract
"Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence." The American journal of drug and alcohol abuse 33, no. 5 (2007): 643-54. Abstract
"HIV testing and sexual risk reduction counseling in office-based buprenorphine/naloxone treatment." Journal of addiction medicine 7, no. 6 (2013): 410-6. Abstract
"Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians." Journal of addiction medicine 6, no. 2 (2012): 159-65. Abstract
"Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine." American journal of preventive medicine 44, no. 1 Suppl 2 (2013): S86-90.
"The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment." Journal of general internal medicine 25, no. 9 (2010): 936-41. Abstract
"Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 11, no. 2 (2002): 111-23. Abstract
"Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S33-8. Abstract
"Coordination of medical care and opioid dependence treatment in primary care: a case report." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 24, no. 1 (2003): 43-6.
"Treatment of heroin dependence with buprenorphine in primary care." The American journal of drug and alcohol abuse 28, no. 2 (2002): 231-41. Abstract
"Opioid Dependence Treatment in the Emergency Department--Reply." JAMA 314, no. 8 (2015): 835.
"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence." The New England journal of medicine 355, no. 4 (2006): 365-74. Abstract
"Treatment of adolescent opioid dependence: no quick fix." JAMA : the journal of the American Medical Association 300, no. 17 (2008): 2057-9.
"Consensus statement on office-based treatment of opioid dependence using buprenorphine." Journal of substance abuse treatment 27, no. 2 (2004): 153-9. Abstract
"Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years." The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions 17, no. 2 (2008): 116-20. Abstract
"Opioid dependence: rationale for and efficacy of existing and new treatments." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S173-7. Abstract
"Buprenorphine: effective treatment of opioid addiction starts in the office." American family physician 73, no. 9 (2006): 1513-4.
"Integration of buprenorphine for substance-abuse treatment by HIV care providers." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S1-2.
"Oral substitution treatment of injecting opioid users for prevention of HIV infection." Cochrane database of systematic reviews (Online), no. 8 (2011): CD004145. Abstract
"Evaluation of a combined online and in person training in the use of buprenorphine." Substance abuse : official publication of the Association for Medical Education and Research in Substance Abuse 27, no. 3 (2006): 39-45. Abstract
"Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial." Addictive behaviors 35, no. 5 (2010): 537-40. Abstract
"Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?" CNS drugs 22, no. 2 (2008): 99-111. Abstract
"Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes." Drug and alcohol dependence 131, no. 1-2 (2013): 127-35. Abstract
"Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients." Drug and alcohol dependence 99, no. 1-3 (2009): 132-40. Abstract
"Buprenorphine and HIV primary care: new opportunities for integrated treatment." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 43 Suppl 4 (2006): S169-72. Abstract
"Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S39-45. Abstract
"Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine." Journal of acquired immune deficiency syndromes (1999) 56 Suppl 1 (2011): S83-90. Abstract
